Massive study to uncover hidden risks in heart patients with metabolic issues

NCT ID NCT07309913

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow about 3,500 adults in China who have atrial fibrillation (an irregular heartbeat) along with metabolic disorders like obesity, diabetes, or high cholesterol. Researchers want to learn how these combined conditions affect risks for stroke, heart failure, and death. The goal is to fill gaps in current knowledge and help create better treatment guidelines for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better management guidelines for people with both atrial fibrillation and metabolic disorders like obesity or diabetes.

What could go wrong

This is an observational study, not a treatment trial. It will not test any new drug or intervention, so it cannot directly improve health outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.